VIP and Parkinson disease: However, EX-4 administration in the pre-motor model of PD prevented astrocytic activation, olfactory and cognitive impairments, the loss of PNNs and the reduction of some CBPs and VIP expression in the PC, through GLP-1R activation, since the effects were prevented by the competitive GLP-1R antagonist EX9-39.